ATE366804T1 - Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung - Google Patents

Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung

Info

Publication number
ATE366804T1
ATE366804T1 AT99925265T AT99925265T ATE366804T1 AT E366804 T1 ATE366804 T1 AT E366804T1 AT 99925265 T AT99925265 T AT 99925265T AT 99925265 T AT99925265 T AT 99925265T AT E366804 T1 ATE366804 T1 AT E366804T1
Authority
AT
Austria
Prior art keywords
sub
pharmaceuticals
manufacturing
line
formulae
Prior art date
Application number
AT99925265T
Other languages
English (en)
Inventor
Paolo Veronesi
Pablo Rodriguez
Original Assignee
Therapicon Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapicon Srl filed Critical Therapicon Srl
Application granted granted Critical
Publication of ATE366804T1 publication Critical patent/ATE366804T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
AT99925265T 1998-05-22 1999-05-20 Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung ATE366804T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI001148A ITMI981148A1 (it) 1998-05-22 1998-05-22 Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie

Publications (1)

Publication Number Publication Date
ATE366804T1 true ATE366804T1 (de) 2007-08-15

Family

ID=11380089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925265T ATE366804T1 (de) 1998-05-22 1999-05-20 Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung

Country Status (10)

Country Link
US (3) US7229809B2 (de)
EP (1) EP1105467B9 (de)
JP (1) JP2002516087A (de)
AT (1) ATE366804T1 (de)
AU (1) AU4163199A (de)
DE (1) DE69936527T2 (de)
ES (1) ES2292244T3 (de)
IT (1) ITMI981148A1 (de)
PT (1) PT1105467E (de)
WO (1) WO1999061593A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
JP2005047844A (ja) * 2003-07-28 2005-02-24 Hiroshi Yamazaki 生物由来高分子物質の分解物、これを含む食品、化粧品、及び医薬品並びにそれらの製造方法
ITMI20052327A1 (it) * 2005-12-06 2007-06-07 Therapicon Srl Lisozima umano ricombinante modificato
DK2254591T3 (da) * 2008-02-08 2017-11-06 Prothera Inc Inhibering eller behandling af gastrointestinal biofilm
JP2013511555A (ja) * 2009-11-23 2013-04-04 スティーブン エフ オルムステッド 特定の症状に関連するバイオフィルムの抑制及び治療のための、セラチア・ペプチダーゼを含む組成物及び方法
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
CN109528498B (zh) * 2018-12-30 2021-05-18 美釉(西安)生物技术有限公司 一种用于深入封闭牙小管并防止生物膜形成的牙齿脱敏剂
EP3981422B1 (de) * 2019-07-19 2024-05-01 Guangzhou Century Clinical Research Co., Ltd Pharmazeutische zusammensetzung mit lysozym und verwendung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie

Also Published As

Publication number Publication date
ITMI981148A1 (it) 1999-11-22
US20030124110A1 (en) 2003-07-03
AU4163199A (en) 1999-12-13
DE69936527T2 (de) 2008-03-13
ES2292244T3 (es) 2008-03-01
EP1105467B1 (de) 2007-07-11
EP1105467B9 (de) 2008-02-13
PT1105467E (pt) 2007-08-13
US7229809B2 (en) 2007-06-12
US7012062B2 (en) 2006-03-14
JP2002516087A (ja) 2002-06-04
US20030129181A1 (en) 2003-07-10
EP1105467A1 (de) 2001-06-13
WO1999061593A1 (en) 1999-12-02
DE69936527D1 (de) 2007-08-23
US20070086993A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
ATE216360T1 (de) Sulfinsäurederivate und deren herstellung und verwendung
MC2040A1 (fr) Derives d'acides amines
BG102162A (en) Substituted (sulpphinic acid, sulphonic acid, sulphonylamino or sulphinylamino)n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylam ide compounds
ES2151156T3 (es) Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados.
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
MC2022A1 (fr) Derives d'acides amines
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
MC2151A1 (fr) Derives d'acides amines
CA2215695A1 (en) .beta.-sheet mimetics and use thereof as protease inhibitors
ATE366804T1 (de) Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung
MY115211A (en) Novel amino acid derivatives, their preparation and use
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
ES2007177A6 (es) Procedimiento para preparar amidas y tioamidas del acido 1'-desoxi-1'-(6-amino-9-purinil)-b-d-ribofuranuronico sustituidas en la posicion 2.
MC1985A1 (fr) Derives d'acides amines
DE59006688D1 (de) Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung.
BR9803914A (pt) Lantibióticos relacionados a actagardina e processos para sua preparação e uso.
CA2267945A1 (en) Anticonvulsant derivatives useful in treating neuropathic pain
MC2107A1 (fr) Derives d'acides amines
CA2192786A1 (en) Cyclopeptolide inhibitors of adhesion molecules
EE9800141A (et) Amidiini ja isotiokarbamiidi derivaadid lämmastikoksiidi süntaasi inhibiitoritena
DK526087A (da) Antikonvulsive aminosyrederivater
AU683790B2 (en) Nitric esters from derivatives of 2-(2-6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
BR9807785A (pt) Processo para a preparação do composto, e, composto

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee